- | 135242-69-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: -
• 英文别名: benzil ketal；benzilketal；2,2-Dihydroxy-1,2-diphenylethanone
• CAS: 135242-69-2
• 化学式: C₁₄H₁₂O₃
• 分子量: 228.247
• InChiKey: IJKJMBDAPXNQJB-UHFFFAOYSA-N

物化性质

• 熔点：
  163 °C
• 沸点：
  389.4±37.0 °C(Predicted)
• 密度：
  1.285±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  二苯基乙酮 在 lithium diisopropyl amide 、 MoO5*pyridine*HMPA 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 以34%的产率得到安息香精油
  参考文献：
  名称：

  HYDROXYLATION OF ENOLATES WITH OXODIPEROXYMOLYBDENUM(PYRIDINE)(HEXAMETHYLPHOSPHORIC TRIAMIDE), MoO5·Py·HMPA(MoOPH): 3-HYDROXY-1,7,7-TRIMETHYLBICYCLO[2.2.1]HEPTAN-2-ONE

  摘要：

  DOI：

  10.15227/orgsyn.064.0127

文献信息

• [EN] FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS MER TYROSINE KINASE (MERTK) INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS DE 2,4-DIAMINOPYRIMIDINE FLUORÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA TYROSINE KINASE MER (MERTK) ET LEURS UTILISATIONS
  申请人：TRILLIUM THERAPEUTICS INC

  公开号：WO2019006548A1

  公开（公告）日：2019-01-10

  A class of fluorinated 2,4-diaminopyrimidine compounds of Formula (I) have been prepared for use in the treatment of cancers and other MERTK related disorders. (Formula (I))

  一类氟代2,4-二氨基嘧啶化合物的化学式（I）已经制备用于治疗癌症和其他与MERTK相关的疾病。 (化学式（I))
• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：PROPELLON THERAPEUTICS INC

  公开号：WO2019046944A1

  公开（公告）日：2019-03-14

  The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：(I) 包括这些化合物的组合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、紊乱或状况的药物。
• [EN] TELOMERASE ACTIVATING COMPOUNDS FOR USE IN FERTILITY AND RELATED APPLICATIONS<br/>[FR] COMPOSÉS ACTIVANT LA TÉLOMÉRASE DESTINÉS À ÊTRE UTILISÉS DANS LA FERTILITÉ ET APPLICATIONS ASSOCIÉES
  申请人：BEN GURION UNIV OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY

  公开号：WO2018146689A1

  公开（公告）日：2018-08-16

  The present invention is directed to methods and uses of a series of compounds and compositions comprising the same for treating diseases, disorders and/or conditions related to fertility and preserving same and conditions related to same. In some aspects, the compounds and or compositions as herein described promote, improve, recover or restore fertility in a subject in need thereof, including in male and/or female subjects. Such methods/uses include promoting, enhancing or improving fertility-associated cell or tissue yield as part of an in vitro fertilization protocol.

  本发明涉及一系列化合物和组合物的方法和用途，用于治疗与生育能力相关的疾病、紊乱和/或状况，并保护与之相关的状况。在某些方面，所述的化合物和/或组合物促进、改善、恢复或恢复需要的受试者的生育能力，包括男性和/或女性受试者。这些方法/用途包括在体外受精方案的一部分中促进、增强或改善与生育能力相关的细胞或组织产量。
• BENZIMIDAZOLE-2-PIPERAZINE HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PREPARATION METHOD AND USE THEREOF
  申请人：SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO., LTD

  公开号：US20160159776A1

  公开（公告）日：2016-06-09

  The present invention relates to a class of benzimidazole-2-piperazine heterocyclic derivatives, a preparation method and medical use thereof. Specifically, the present invention relates to a new benzimidazole-2-piperazine heterocyclic derivative of general Formula (I), a preparation method, a pharmaceutical composition containing the same, and use thereof as a therapeutic agent and especially as a poly(ADP-ribose)polymerase (PARP) inhibitor.

  本发明涉及一类苯并咪唑-2-哌嗪杂环衍生物、其制备方法及其医疗用途。具体而言，本发明涉及一种通式（I）的新苯并咪唑-2-哌嗪杂环衍生物、其制备方法、含有该衍生物的药物组合物，以及作为治疗剂特别是作为聚（ADP-核糖）聚合酶（PARP）抑制剂的用途。
• Substituted piperazines as metabotropic glutamate receptor antagonists
  申请人：Edwards Louise

  公开号：US20070037820A1

  公开（公告）日：2007-02-15

  The invention relates to compounds of formula I or pharmaceutically acceptable salts or solvates thereof: where Ar 1 , Ar 2 , Hy, L, R 1 , m and n are as defined in the description. The invention also includes pharmaceutical compositions and uses thereof, processes for making the compounds, as well as methods for the medical treatment of mGluR5-mediated disorders.

  这项发明涉及公式I的化合物或其药用可接受的盐或溶剂： 其中Ar1，Ar2，Hy，L，R1，m和n如描述中所定义。该发明还包括药物组合物及其用途，制备这些化合物的方法，以及治疗mGluR5介导的疾病的方法。